{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:55:54Z","timestamp":1759938954360},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eprotirome, a liver specific thyroid hormone agonist, was shown to induce significant increases in markers of liver injury along with a modest decrease in atherogenic lipids and lipoproteins. To get more insight into whether these effects on liver parameters were compound specific or the effect of mimicking thyrotoxicosis, we studied the effects of supra-physiological levothyroxine dosages on liver parameters, lipids and lipoproteins. We used data of a single-blinded, randomized controlled crossover trial. Herein, healthy volunteers received levothyroxine or no medication for 14 days. Thyroid hormone excess did not induce clinically relevant changes in liver parameters, while significant reductions in total cholesterol, low-density lipoprotein-cholesterol as well as apolipoprotein-B levels were observed in the intervention periods compared with the control periods. Supra-physiological thyroid hormone levels did not induce clinically relevant increases in markers of liver injury after 2 weeks of exposure, while it reduced total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B levels. This suggests that the effects of eprotirome on liver parameters in previous studies were either off-target and compound specific or due to drug-drug interaction at the level of the liver. The results of our study are relevant for the development of novel thyroid hormone agonists to reduce atherogenic lipoproteins.<\/jats:p>","DOI":"10.1038\/s41598-017-14526-2","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T15:07:31Z","timestamp":1508512051000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of Supra-Physiological Levothyroxine Dosages on Liver Parameters, Lipids and Lipoproteins in Healthy Volunteers: A Randomized Controlled Crossover Study"],"prefix":"10.1038","volume":"7","author":[{"given":"Barbara","family":"Sjouke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura P. B.","family":"Elbers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bregje","family":"van Zaane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J. P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor E. A.","family":"Gerdes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"14526_CR1","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1001\/archinte.1995.00430140052004","volume":"155","author":"T Diekman","year":"1995","unstructured":"Diekman, T., Lansberg, P. J., Kastelein, J. J. & Wiersinga, W. M. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch.Intern.Med. \n                           155, 1490\u20131495 (1995).","journal-title":"Arch.Intern.Med."},{"key":"14526_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1089\/thy.2000.10.803","volume":"10","author":"T Tzotzas","year":"2000","unstructured":"Tzotzas, T., Krassas, G. E., Konstantinidis, T. & Bougoulia, M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid \n                           10, 803\u2013808 (2000).","journal-title":"Thyroid"},{"key":"14526_CR3","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1210\/jc.2009-1209","volume":"95","author":"PW Ladenson","year":"2010","unstructured":"Ladenson, P. W. et al. Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J.Clin.Endocrinol.Metab \n                           95, 1349\u20131354 (2010).","journal-title":"J.Clin.Endocrinol.Metab"},{"key":"14526_CR4","first-page":"901","volume":"75","author":"SI Sherman","year":"1992","unstructured":"Sherman, S. I. & Ladenson, P. W. Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects. J.Clin.Endocrinol.Metab \n                           75, 901\u2013905 (1992).","journal-title":"J.Clin.Endocrinol.Metab"},{"key":"14526_CR5","first-page":"52","volume":"82","author":"J Stamler","year":"1977","unstructured":"Stamler, J. The coronary drug project\u2013findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv.Exp.Med.Biol. \n                           82, 52\u201375 (1977).","journal-title":"Adv.Exp.Med.Biol."},{"key":"14526_CR6","first-page":"912","volume":"10","author":"I Tancevski","year":"2009","unstructured":"Tancevski, I., Eller, P., Patsch, J. R. & Ritsch, A. The resurgence of thyromimetics as lipid-modifying agents. Curr Opin Investig Drugs \n                           10, 912\u2013918 (2009).","journal-title":"Curr Opin Investig Drugs"},{"key":"14526_CR7","unstructured":"Karo Bio, 2012. Press Release. Available at http:\/\/karopharma.se\/en\/karo-bio-terminates-theeprotirome-program\/ Accessed 16 October 2017."},{"key":"14526_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S2213-8587(14)70006-3","volume":"2","author":"B Sjouke","year":"2014","unstructured":"Sjouke, B. et al. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes Endocrinol \n                           2, 455\u2013463 (2014).","journal-title":"Lancet Diabetes Endocrinol"},{"key":"14526_CR9","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1111\/j.1538-7836.2011.04430.x","volume":"9","author":"B Van Zaane","year":"2011","unstructured":"Van Zaane, B. et al. Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: a controlled randomized crossover study. J Thromb Haemost \n                           9, 1816\u20131824 (2011).","journal-title":"J Thromb Haemost"},{"key":"14526_CR10","first-page":"444","volume":"102","author":"JS Rogers 2nd","year":"1983","unstructured":"Rogers, J. S. 2nd & Shane, S. R. Factor VIII activity in normal volunteers receiving oral thyroid hormone. J Lab Clin Med \n                           102, 444\u2013449 (1983).","journal-title":"J Lab Clin Med"},{"key":"14526_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3164\/jcbn.2008036","volume":"43","author":"N Fukuyama","year":"2008","unstructured":"Fukuyama, N. et al. Validation of the Friedewald Equation for Evaluation of Plasma LDL-Cholesterol. J Clin Biochem Nutr \n                           43, 1\u20135 (2008).","journal-title":"J Clin Biochem Nutr"},{"key":"14526_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.mcna.2012.01.012","volume":"96","author":"LH Duntas","year":"2012","unstructured":"Duntas, L. H. & Brenta, G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am \n                           96, 269\u2013281 (2012).","journal-title":"Med Clin North Am"},{"key":"14526_CR13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/MOL.0000000000000024","volume":"24","author":"RM Stoekenbroek","year":"2013","unstructured":"Stoekenbroek, R. M., Kastelein, J. J. & Hovingh, G. K. Recent failures in antiatherosclerotic drug development: examples from the thyroxin receptor agonist, the secretory phospholipase A2 antagonist, and the acyl coenzyme A: cholesterol acyltransferase inhibitor programs. Curr Opin Lipidol \n                           24, 459\u2013466 (2013).","journal-title":"Curr Opin Lipidol"},{"key":"14526_CR14","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0905633","volume":"362","author":"PW Ladenson","year":"2010","unstructured":"Ladenson, P. W. et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N.Engl.J.Med. \n                           362, 906\u2013916 (2010).","journal-title":"N.Engl.J.Med."},{"key":"14526_CR15","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1210\/en.2011-2081","volume":"153","author":"JZ Lin","year":"2012","unstructured":"Lin, J. Z. et al. Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor. Endocrinology \n                           153, 6136\u20136144 (2012).","journal-title":"Endocrinology"},{"key":"14526_CR16","first-page":"103","volume":"28","author":"A Gurlek","year":"1996","unstructured":"Gurlek, A., Cobankara, V. & Bayraktar, M. Changes in liver biochemical tests at diagnosis and after propylthiouracil therapy for hyperthyroidism. Mater Med Pol \n                           28, 103\u2013106 (1996).","journal-title":"Mater Med Pol"},{"key":"14526_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/00004836-199704000-00013","volume":"24","author":"A Gurlek","year":"1997","unstructured":"Gurlek, A., Cobankara, V. & Bayraktar, M. Liver tests in hyperthyroidism: effect of antithyroid therapy. J. Clin. Gastroenterol. \n                           24, 180\u2013183 (1997).","journal-title":"J. Clin. Gastroenterol."},{"key":"14526_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1089\/thy.2007.0189","volume":"18","author":"S Kubota","year":"2008","unstructured":"Kubota, S. et al. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves\u2019 disease and painless thyroiditis. Thyroid \n                           18, 283\u2013287 (2008).","journal-title":"Thyroid"},{"key":"14526_CR19","doi-asserted-by":"publisher","first-page":"15490","DOI":"10.1073\/pnas.0702759104","volume":"104","author":"MD Erion","year":"2007","unstructured":"Erion, M. D. et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proceedings of the National Academy of Sciences of the United States of America \n                           104, 15490\u201315495 (2007).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"14526_CR20","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0735-1097(16)31933-7","volume":"67","author":"B Lian","year":"2016","unstructured":"Lian, B., Hanley, R. & Schoenfeld, S. A phase 1 randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate safety, tolerability and pharmacokinetics of the liver-selective TR-beta agonist VK2809 (MB07811) in hypercholesterolemic subjects. J Am Coll Cardiol \n                           67, 1932 (2016).","journal-title":"J Am Coll Cardiol"},{"key":"14526_CR21","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"MJ Kelly","year":"2014","unstructured":"Kelly, M. J. et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dio xo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor beta agonist in clinical trials for the treatment of dyslipidemia. Journal of medicinal chemistry \n                           57, 3912\u20133923 (2014).","journal-title":"Journal of medicinal chemistry"},{"key":"14526_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","volume":"230","author":"R Taub","year":"2013","unstructured":"Taub, R. et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis \n                           230, 373\u2013380 (2013).","journal-title":"Atherosclerosis"},{"key":"14526_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1073\/pnas.0705286104","volume":"105","author":"A Berkenstam","year":"2008","unstructured":"Berkenstam, A. et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc.Natl.Acad.Sci.USA \n                           105, 663\u2013667 (2008).","journal-title":"Proc.Natl.Acad.Sci.USA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14526-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14526-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14526-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T12:46:23Z","timestamp":1671799583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14526-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["14526"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-14526-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]},"assertion":[{"value":"22 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14174"}}